标题：Pharmacogenetics of statins treatment: Efficacy and safety
作者：Guan, Zi-Wan; Wu, Kun-Rong; Li, Rui; Yin, Ying; Li, Xiao-Li; Zhang, Shu-Fang; Li, Yan
作者机构：[Guan, Zi-Wan; Wu, Kun-Rong; Li, Rui] Shandong Univ, Sch Pharmaceut Sci, Jinan, Shandong, Peoples R China.; [Guan, Zi-Wan; Wu, Kun-Rong; Li, Rui; Li 更多
通讯作者地址：[Li, Y]Shandong Univ, Shandong Prov Qianfoshan Hosp, Jinan, Shandong, Peoples R China.
来源：JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
关键词：cytochrome P450; gene polymorphism; pharmacogenetics; statins;; transporter
摘要：What is known and objective Statins are widely used worldwide in the prevention and treatment of coronary atherosclerotic heart disease and ischaemic stroke. However, in clinical application, statins have shown great individual differences in terms of the efficacy and safety, some of which are related to genetic factors. The purpose of this article was to summarize the recent advances about the correlation between gene polymorphisms and the efficacy/safety of statins. Methods We searched the databases including PharmGKB and PubMed (published before June 2019) using the keywords such as 'statin', 'gene polymorphism' and 'SNP' and obtained more than 100 articles. In this review, we described the clinical studies of genetic variants associated with both the efficacy and adverse reactions of statins. We also clarified the importance of taking pharmacogenetic variation into account to improve the clinical application of statins. Results and discussion The available data were collected and analysed to present the polymorphisms of candidate genes encoding the most promising proteins including SLCO1B1 (encoding uptake transporters); ABCB1, ABCC2, ABCG2 (encoding effluent transporter); APOE, APOA5 (encoding apolipoprotein); genes encoding cytochrome P450 enzyme system; KIF6, HMGCR, LDLR, LPA, PCSK9, COQ2, CETP, etc These genes were proved to be related to the pharmacodynamics and pharmacokinetics of statins, thus affecting the efficacy and safety. What is new and conclusion In this paper, the correlation between gene polymorphisms and the efficacy/safety of statins was summarized. The authors reached a consensus that the variants of the genes encoding uptake and effluent transporters have the most effect on the efficacy/safety of statins. It pointed out that it is desirable to do genetic testing of these transporter genes to reduce the incidence of myopathy or to achieve better outcomes before patients use statins, especially in the regions with high frequency of risk allele.